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Multiple sclerosis (MS) is a common inflammatory disease of the
central nervous system unsurpassed for variability in disease out-
come. A cohort of sporadic MS cases (n 163), taken from opposite
extremes of the distribution of long-term outcome, was used to
determine the role of the HLA-DRB1 locus on MS disease severity.
Genotyping sets of benign and malignant MS patients showed that
HLA-DRB1*01 was significantly underrepresented in malignant
compared with benign cases. This allele appears to attenuate the
progressive disability that characterizes MS in the long term. The
observation was doubly replicated in (i) Sardinian benign and
malignant patients and (ii) a cohort of affected sibling pairs
discordant for HLA-DRB1*01. Among the latter, mean disability
progression indices were significantly lower in those carrying the
HLA-DRB1*01 allele compared with their disease-concordant sib-
lings who did not. The findings were additionally supported by
similar transmission distortion of HLA-DRB1*04 subtypes closely
related to HLA-DRB1*01. The protective effect of HLA-DRB1*01 in
sibling pairs may result from a specific epistatic interaction with the
susceptibility allele HLA-DRB1*1501. A high-density (>700) SNP
examination of the MHC region in the benign and malignant
patients could not identify variants differing significantly between
the two groups, suggesting that HLA-DRB1 may itself be the
disease-modifying locus. We conclude that HLA-DRB1*01, previ-
ously implicated in disease resistance, acts as an independent
modifier of disease progression. These results closely link suscep-
tibility to long-term outcome in MS, suggesting that shared quan-
titative MHC-based mechanisms are common to both, emphasizing
the central role of this region in pathogenesis.
There can be few diseases with as much variation in outcomeas seen in multiple sclerosis (MS). Clinical manifestations,
disease course, severity, and underlying pathological processes
vary considerably among patients (1–6). For some it is a lifelong
occasional nuisance, whereas for others it can be fatal in1 year.
Clinical and demographic factors have been associated with
variation in disease severity and course, but efforts to elicit
biological factors that determine such heterogeneity have to date
not been fruitful.
There is reason to believe that genes may not only play a role
inMS susceptibility (7), but also in clinical outcome as evidenced
by twin studies. These data indicate that monozygotic twins are
much more concordant for disease course than dizygotic twins
or siblings (8). Further evidence of common genetic variants
influencing disease severity exists in other putative autoimmune
disorders, such as rheumatoid arthritis (9, 10).
The major histocompatibility complex (MHC) is associated
with many putative autoimmune diseases, including MS (11–13).
In the case of MS, susceptibility is unambiguously linked to the
HLA class II region with susceptibility associated with the
extended haplotype HLA-DQA1*0102-DQB1*0602-
DRB1*1501-DRB5*0101 (14). Several studies have investigated
the role of HLA alleles on disease outcome; however, the results
have been unclear and conflicting (15–24). Among affected
individuals, despite the presence of a common susceptibility
region, there is marked clinical heterogeneity. Both the quality
of clinical manifestations and the degree of disability outcomes
vary substantially from patient to patient.
Approaches to this question have typically used unselected
populations and cross-sectional measures or less often, rates of
disability over time. This strategy is often underpowered because
the outcome measures used in studies of this type frequently
encompass only a minority of the entire disease spectrum.
Effects sought may be effectively diluted by the frequent inclu-
sion of patients yet to reach important outcome milestones.
Insight into any role that the HLA class II region might play in
determining clinical outcome in MS could come from the
comparison of HLA-DRB1 alleles in patients who are extremely
discordant for long-term clinical outcome. This approach is
demonstrably more powerful (25–27).
The present study investigates the role of HLA-DRB1 alleles
in influencing disease outcome in sporadic MS cases lying at
opposite extremes of the distribution of long-term outcome
(benign vs. malignant disease) identified with stringent clinical
criteria. This unique cohort provides 99% power to detect a
quantitative trait locus contributing to 2% of the additive
phenotypic variance. This calculation assumes a normal distri-
bution of disability in theMS population, with no dominance and
an allele frequency of 0.2, tagged by a biallelic marker in
complete linkage disequilibrium with the disease locus.
An additional feature of this study is the use of an independent
cohort of affected sibling pairs (i.e., both siblings affected with
the disease), a type of affected relative pair widely available for
many complex traits. This cohort permits the validation of a
positive allelic association with disease outcome identified in
‘‘extremes’’ cohorts. Rates of disease progression can be directly
compared within sibling pairs discordant for the allele in ques-
tion. To clarify whether HLA-DRB1 or genes/regulatory regions
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in linkage disequilibrium with this locus mediate effects on
disease progression, we genotyped a high-density SNP panel
spanning the genes within the MHC and its f lanking regions. A
role forHLA-DRB1*01 in protecting against disease progression
in MS was supported.
Results
The Influence of HLA-DRB1 Alleles on MS Susceptibility. The allele
phenotype frequencies for each of the HLA-DRB1 alleles were
compared in the sporadic MS cases vs. controls (Table 1). As
expected, a significantly greater proportion of MS patients was
positive for theHLA-DRB1*15 allele compared with the controls
(56% vs. 24%; P  0.0001). The only other allele to differ
betweenMS patients and controls was theHLA-DRB1*11 allele,
which was underrepresented in the MS cases (7.9% vs. 15%; P
0.05). A separate study investigating HLA-DRB1 alleles in a
cohort of affected sibling pairs showed a similar frequency
profile to our sporadic MS cohort (28). To determine whether or
not the strong association with the HLA-DRB1*15 allele created
misleading deviations in the frequencies of the other alleles, the
relative predispositional effects comparison method was used. It
revealed that the HLA-DRB1*17 allele trended toward being
overrepresented in MS patients compared with controls
(P  0.06).
The Influence of HLA-DRB1 Alleles on Disease Outcome. Upon strat-
ification of the MS cases into benign and malignant subtypes, an
underrepresentation of the HLA-DRB1*01 allele in malignant
MS (MMS) was observed when compared with benign MS
(BMS) (BMS, 19%; MMS, 3.9%, P  0.027) (Table 2). This
association was independent of gender and confirmed by logistic
regression. No other alleles differed significantly between MS
outcome groups, including the HLA-DRB1*15 allele (BMS,
56%; MMS, 57%), and the overall frequency distribution of the
alleles was not statistically significant between them.
The genotype (1-1, 1-X, X-X) frequencies between BMS and
MMS were compared (where 1 is the HLA-DRB1*01 allele and
X represents any HLA-DRB1 allele other than HLA-DRB1*01).
A significant underrepresentation of the frequency of genotypes
containing the HLA-DRB1*01 allele (i.e., 1-1, 1-X) in MMS vs.
BMS was observed (Table 3).
The HLA-DRB1*15 allele has been occasionally associated
with more severe disease outcome. In the current study, no
significant differences in genotype frequencies between out-
come groups were found. However, a somewhat greater pro-
portion of malignant cases were homozygous for HLA-DRB1*15
compared with BMS (MMS, 15% vs. BMS, 8%).
HLA-DRB1 Alleles in HLA-DRB1*15 Negative Patients. To investigate
the effect of alleles other than HLA-DRB1*15 on disease out-
come, the allele phenotype frequencies of patients and controls
negative for the HLA-DRB1*15 allele were compared. MMS
patients carriedHLA-DRB1*01 significantly less than BMS cases
(MMS, 11% vs. BMS, 43%, P  0.039). In addition, the
HLA-DRB1*01 allele was significantly overrepresented in BMS
compared with controls (BMS, 43% vs. control, 24%; P 0.033).
Interaction of HLA-DRB1 Alleles and Its Influence on Disease Outcome.
To determine whether or not interactions between HLA-DRB1
alleles influenced disease outcome, the HLA-DRB1 alleles that
differed significantly from controls were tested for interactions
by using logistic regression. No significant interactions were








P value OR (95% C.I.)
1 23 (14%) 41 (20%) NS
4 39 (24%) 59 (29%) NS
7 25 (15%) 49 (24%) NS
8 11 (6.7%) 9 (4.5%) NS
9 1 (0.61%) 7 (3.5%) NS
10 1 (0.61%) 2 (0.99%) NS
11 13 (7.9%) 31 (15%) 0.050 0.51 (0.26–0.98)
12 5 (3.1%) 10 (5.0%) NS
13 33 (20%) 47 (23%) NS
14 6 (3.7%) 12 (5.9%) NS
15 92 (56%) 49 (24%) 0.0001 3.00 (2.03–4.43)
16 3 (1.8%) 8 (4.0%) NS
17 40 (25%) 45 (22%) NS
NS, not significant.








BMS vs. MMS BMS vs. control MMS vs. control
P value OR (95% C.I.) P value OR (95% C.I.) P value OR (95% C.I.)
1 21 (19%) 2 (3.9%) 41 (20%) 0.027 4.85 (1.11–21.16) NS 0.016 0.19 (0.04–0.79)
4 27 (24%) 12 (24%) 59 (29%) NS NS NS
7 17 (15%) 8 (16%) 49 (24%) NS NS NS
8 9 (8.0%) 2 (3.9%) 9 (4.5%) NS NS NS
9 0 (0%) 1 (2.0%) 7 (3.5%) NS 0.049 0 NS
10 1 (0.89%) 0 (0%) 2 (0.99%) NS NS NS
11 6 (5.4%) 7 (14%) 31 (15%) NS 0.013 0.33 (0.13–0.80) NS
12 4 (3.6%) 1 (2.0%) 10 (5.0%) NS NS NS
13 20 (18%) 13 (25%) 47 (23%) NS NS NS
14 5 (4.5%) 1 (2.0%) 12 (5.9%) NS NS NS
15 63 (56%) 29 (57%) 49 (24%) NS 0.0001 2.90 (1.90–4.42) 0.0001 3.27 (1.91–5.59)
16 2 (1.8%) 1 (2.0%) 8 (4.0%) NS NS NS
17 30 (27%) 10 (20%) 45 (22%) NS NS NS
NS, not significant.
Table 3. HLA-DRB1*01 genotype frequencies in BMS and MMS
Genotype BMS, n MMS, n Total, n
1-1 2 (2%) 0 (0%) 2
1-X 19 (17%) 2 (4%) 21
X-X 91 (81%) 49 (96%) 140
Total 112 51 163











found between any of these risk and protective alleles on disease
outcome. In addition, the HLA-DRB1 allele frequencies in
patients who are positive for HLA-DRB1*15 were compared.
The HLA-DRB1*01 allele was underrepresented in both BMS
and MMS when compared with unaffected controls.
Transmission Disequilibrium Test (TDT) Analysis.ATDT analysis was
performed to test for transmission distortion of the HLA-DRB1
alleles. The HLA-DRB1*01 allele was significantly undertrans-
mitted in MMS but not in BMS. TDT analysis also showed that
HLA-DRB1*15 was preferentially overtransmitted to malignant
(5:1) compared with benign cases (2.3:1) (Table 4). To control
for the overrepresentation of the HLA-DRB1*15 allele, a TDT
analysis using HLA-DRB1*15 negative parents was used. It was
found that the HLA-DRB1*01 allele was undertransmitted to
affected offspring with MMS. There was no evidence of trans-
mission distortion for any of the other alleles investigated in
BMS, MMS, or all MS cases combined. However, the number of
families wherein both parents were HLA-DRB1*15 negative was
small (n  13), and these results should be taken with caution.
Validation of Protective Effect of HLA-DRB1*01 on Disease Outcome.
Independent affected sibling-pair cohort. To validate the protective
effect of the HLA-DRB1*01 allele on disease outcome, the
progression indices (disability scores/time) of a prospective
cohort of affected sibling pairs discordant for theHLA-DRB1*01
allele were compared by using a Wilcoxon paired samples test.
The results confirm the protective effect conferred by the
HLA-DRB1*01 allele as the sibling carrying the HLA-DRB1*01
allele had a progression index (PI) of 0.27 compared with 0.57
for the sibling not carrying the protective allele (P  0.009). In
other words, the affected sibling with the HLA-DRB1*01 allele
reached an Expanded Disability Status Scale (EDSS)  6 in a
mean of 22.2 years of disease onset compared with the affected
sibling without HLA-DRB1*01, who reached the same level of
disability 10.5 years after disease onset. Upon further analysis of
the sibling cohort data, the protective effect conferred by the
HLA-DRB1*01 allele is only significant when it is part of the
HLA-DRB1*15-HLA-DRB1*01 (15-1) genotype (15-1, PI 
0.25; 1-X, PI  0.49; P  0.01; where X represents any
HLA-DRB1 allele other than HLA-DRB1*01 and HLA-
DRB1*15).
Sardinian cohort. We genotyped benign and malignant patients
from Sardinia for the presence ofHLA-DRB1*01. There were 19
benign and 0 malignant patients positive for the allele (P 
0.006).
HLA-DRB1 subtypes. HLA-DRB1*0101, HLA-DRB1*0401, and
HLA-DRB1*0404 all share a common stretch of amino acids at
positions 67–74 in the peptide binding groove of the DR  chain
(29). Twenty-six of 112 (23%) benign patients were positive for
either HLA-DRB1*0401 and HLA-DRB1*0404, compared with
only 5 of the 51 (10%) malignant patients (P  0.03).
High-Density SNP Typing of theMHC Region. In the Canadian benign
and malignant patients we typed the MHC genomic region with
a dense panel of SNPs. We accepted markers for analysis if they
met the following criteria: (i) a minimum call rate of 90%; (ii)
consistency with Hardy–Weinberg equilibrium at P 0.001; and
(iii) a minimum minor allele frequency of 2%. These criteria
identified 703 successful assays. Using a previously published
definition (30), we identified 104 haplotype blocks spanning the
MHC. Analysis of both single markers and haplotypes could not
identify any statistically significant differences between benign
and malignant patients (Fig. 1). The single SNP marker most
significantly associated with outcome was rs2071541 in the HLA
class II region (P  0.005, uncorrected; see www.well.ox.ac.uk/
sreeramr for a full list of markers and associated P values). No
association remained significant after correction for multiple
testing using a permutation test (n  10,000 permutations).
Given the number of samples and markers used, no SNP may
ever reach significance after correction, so we attempted to
replicate all nominally associated SNPs in the additional cohorts.
No SNP association replicated.
Discussion
The only genetic association withMS in Northern Europeans has
been with extended MHC haplotypes, especially those contain-
ing HLA-DRB1*1501 (7). However, IL-7 receptor (IL7RA) and
IL-2 receptor (IL2RA) alleles have recently been shown to have
slight influence on risk (31, 32). These effects [maximum odds
ratios (OR) 1.3] are much smaller compared with those within
the MHC (OR  5.4). It is now clear that the MHC is the key
susceptibility locus in MS with other susceptibility genes con-
tributing relatively little (33). Reports of linkages or associations
improbably reported on nearly every chromosomal arm appear
to be false positives for the most part (34).
The role of the MHC and, in particular, the HLA-DRB1 locus
in determining clinical outcome in MS has been poorly under-
stood. The present study examines the distribution of HLA-
DRB1 alleles in two types of large MS cohorts. The first consists
of sporadic cases lying at the two extreme ends of long-term
clinical outcome, and the second is the common type of affected
relative pair in this disease–concordant sibling pairs. In the first
cohort of sporadic MS cases, the classic association of the
HLA-DRB1*15 allele to disease susceptibility was confirmed in
both case-control and family-based (i.e., TDT) analyses. In
Table 4. Transmission of HLA-DRB1 alleles in MS
Allele
All MS cases BMS MMS
TR, n NT, n 2 P value TR, n NT, n 2 P value TR, n NT, n 2 P value
1 12 20 2 NS 6 7 0.08 NS 1 7 4.5 0.03
4 21 25 0.35 NS 9 7 0.25 NS 6 8 0.29 NS
7 13 17 0.53 NS 6 6 0 NS 3 4 0.14 NS
8 8 3 2.27 NS 4 0 4 0.05 1 1 0 NS
9 1 0 1 NS 0 0 0 NS 1 0 1 NS
11 6 14 3.2 NS 2 7 2.78 NS 2 2 0 NS
12 4 0 4 0.05 2 0 2 NS 1 0 1 NS
13 10 26 7.11 0.008 1 12 9.31 0.002 2 6 2 NS
14 4 4 0 NS 2 3 0.2 NS 0 1 1 NS
15 49 17 15.52 0.00008 14 6 3.2 NS 15 3 8 0.004
16 2 4 0.67 NS 2 1 0.33 NS 0 0 0 NS
17 13 13 0 NS 6 5 0.09 NS 4 4 0 NS
TR, transmitted; NT, not transmitted; NS, not significant.
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keeping with other studies, a modest association of allele HLA-
DRB1*17 with MS was also observed, after taking into account
the relative predispositional effect of the HLA-DRB1*15 allele
(22, 28). As an independent control for the HLA-DRB1 allele
frequencies noted in this study, the HLA-DRB1 allele frequency
profiles of the sporadic cases were compared with those of a large
independent cohort of affected sibling pairs (28). The distribu-
tion of allele frequencies between cohorts was found to be
remarkably similar. This finding implies that sporadic MS may
not differ qualitatively from familial MS in terms of genetic
susceptibility to the disease and invites direct comparisons.
Several groups investigating HLA class II genotypes in relaps-
ing remitting MS and primary progressive MS have sought
evidence for genetic heterogeneity in MS, but there has been
little consensus to indicate that different alleles confer suscep-
tibility to different clinical subsets of the disease (1, 15, 35).
Comparison of HLA-DRB1 allele profiles between BMS and
MMS in the current dataset showed no difference in allele
frequency for the main associated allele HLA-DRB1*15. These
findings cohere with observations within families and imply that
these extreme clinical phenotypes are not separate disease
entities. Even though MS is clinically heterogeneous in terms of
age of onset, duration of disease, and gender distribution, the
frequency of the main Northern European MS susceptibility
allele,HLA-DRB1*15, was similar in both BMS (56%) andMMS
(57%). Taken together with the observation that few other
diseases [chronic sarcoidosis (36), narcolepsy (37), and perni-
cious anemia (38)] are positively associated with this allele, the
notion that BMS and MMS are probably extreme clinical
manifestations of the same disease finds support.
With similar HLA-DRB1*15 allele frequencies in the ex-
tremes, comparison of the frequency of other alleles conve-
niently isolates their outcome effect on a common roughly
equivalent background of both risk and the major allele associ-
ated with its associated susceptibility. The strategies used effec-
tively minimize the problems of population stratification by these
inherent features of internal matching.
The analyses here yielded several lines of evidence suggesting
that HLA-DRB1*01 protects against adverse clinical outcome in
MS. First, genotyping data from sporadic MS cases showed
HLA-DRB1*01 to be significantly underrepresented in malig-
nant cases compared with both the benign and control groups,
indicating that the absence of the allele may accentuate a
progressive course inMS. The fact that theHLA-DRB1*01 allele
frequency did not differ between benign and control cases
implied this effect diverges from susceptibility itself and deter-
mines outcome rather than risk, but higher-order interactions
have been demonstrated (28). Second, stratification of cases for
HLA-DRB1*15 revealed that HLA-DRB1*01 was significantly
underrepresented in MMS compared with BMS and was over-
represented in BMS compared with controls in cases negative for
HLA-DRB1*15. These findings show that the phenotype-based
allele frequencies ofHLA-DRB1*01 observed in BMS andMMS
are not misleading deviations caused by the strong association of
other alleles, such as HLA-DRB1*15, and that the presence of
HLA-DRB1*01 protects against malignant disease. Third, in a
TDT analysis using the genotype data from nuclear family
members, it was found that the HLA-DRB1*01 allele was
significantly undertransmitted to affected offspring with MMS,
whereas no transmission distortion for this allele was observed
in offspring with benign disease. The results from the TDT
analysis provide another dimension of support to the assertion
that HLA-DRB1*01 protects against the rapid acquisition of
disability in MS, further attenuating the possibility that popu-
lation substructure could confound the data. Fourth, in a
replication cohort of Sardinian benign and malignant patients
there was a significant overrepresentation of HLA-DRB1*01 in
benign patients. Remarkably, this was found despite the primary
MS association in this population being with non-HLA-
DRB1*1501 alleles. Fifth, in an independent cohort of affected
sibling pairs discordant for HLA-DRB1*01, the mean PI was
considerably lower in the sibling carrying the HLA-DRB1*01
allele compared with their affected HLA-DRB1*01-negative
sibling. Not only does the affected sibling-pair dataset serve to
replicate the genotype findings from the sporadic MS cohort, it
serves to validate the claim that the protective effect on clinical
outcome comes from the HLA-DRB1*01 allele or a nearby
variation. Sibling pairs share a common genetic background and
perhaps environmental factors, thereby increasing the likelihood
that a discordant locus or allele (i.e., HLA-DRB1*01) when
associated with a discordant phenotype, contributes to the
clinical picture observed. Finally, although theHLA-DRB1 allele
appears to play a significant role in modifying the disease course
and severity in MS, it is important to emphasize that the
protective effect does not necessarily arise directly from the
HLA-DRB1*01 allele itself. It is plausible that a locus or
regulatory region in tight linkage disequilibrium with the HLA-
DRB1*01 allele, or a more complex protective haplotype, may be
disease-modifying. However, the results of dense SNP typing of
the MHC region did not identify any variants differing signifi-
cantly between benign and malignant patients. Although this
study argues against any involvement of genes encoding the
Fig. 1. Results of high-density SNP typing of the MHC region in benign vs. malignant patients (negative logarithm P value of difference in SNP frequency
between benign and malignant patients plotted against physical position of SNP in MHC).











MHC apart from HLA-DRB1 in determining outcome, it re-
mains possible that the SNP panel used may have missed variants
with disease-modifying activity or was underpowered to do so,
especially given the difficulty with SNP typing in this region (39).
The greater proportion of benign patients positive for either
HLA-DRB1*01 or HLA-DRB1*0401/HLA-DRB1*0404 than of
malignant cases is intriguing. Ironically, such analogy is not
readily ascertained for DRB1 alleles involved in MS susceptibil-
ity, possibly dissociating these two effects. It suggests that the
known shared binding characteristics of these molecules could
pinpoint the precise site that allows them to participate in
underlying severity-related mechanisms. For DRB1*0401/HLA-
DRB1*0404, this finding is converse to the role of these alleles
in rheumatoid arthritis, where these alleles predispose to severe
disease but the genetic pattern seems similar. There are several
reported examples of peptides that bind both HLA-DRB1*0401
and HLA-DRB1*0101 (29).
The finding that the protective effect of HLA-DRB1*01 in
sibling pairs occurs primarily within the HLA-DRB1*15/01 ge-
notype suggests that interactions between specific HLA-DRB1
alleles/haplotypes influence phenotypic expression of MS. This
notion is analogous to what we have previously shown for
susceptibility (28) and also applies to animal models where
epistasis between HLA-DRB1*15 and HLA-DRB5*0101 has
been shown to influence the clinical course of experimental
autoimmune encephalomyelitis (28) (40). Because interactions
between HLA-DRB1*15 and DRB1*01 have been shown to
confer resistance to acquiring the disease, susceptibility and
outcome in MS may be intrinsically linked (28, 41). Overlap
between these effects may only be partial. Although HLA-
DRB1*15 is by far the commonest susceptibility allele, it did not
differ in allele frequency between benign and malignant cases in
contrast to DRB1*01.
There may well be similar effects from other DRB1 resistance
alleles of lower frequency or with smaller effect size on outcome,
which might be most efficiently sought by using larger numbers
of extremes. Given the striking ethnic differences for class II
allele frequency, epistatic mechanisms identified here and pre-
viously are plausible candidates for some of the remarkable
differences inMS outcome that have been reported among racial
groups. Perhaps less obvious is the potential explanation offered
by epistatic effect of the type shown here for population-specific
differences in outcome and allelic association. Here, we showed
that in populations stratified by outcome the primary allelic
association did not differ but the epistatic allele had a major
influence on disability. This finding has potential relevance to
the vexing problems of replicating disease associations, suggest-
ing that some findings attributed to false positivity could be
manifestations of inadvertent comparison of populations un-
matched for important epistatic effects.
In conclusion, HLA-DRB1*01 segregates both with disease
resistance and favorable outcome, is an independent contributor
to the risk of disease progression, and operates in both sporadic
and familial MS (sibling pairs). Future genetic and functional
studies will investigate the manner in which the HLA-DRB1*01
allele exerts its protective effect on outcome. This will be crucial
for developing potential therapeutic strategies based on these
findings, which might modify the progression of this often
devastating disease.
Subjects and Methods
Patients and Controls. All subjects used in the study were ascertained through
the ongoing Canadian Collaborative Project on the Genetic Susceptibility to
MS (CCPGSMS), for which the methodology has been described (42, 43). A total
of 163 sporadic MS patients along with their nuclear family members (n 625)
were selected for analysis from London, Ontario, and Vancouver. The disabil-
ity of the sporadic MS patients was carefully assessed and recorded at entry
with the EDSS by neurologists involved in the CCPGSMS. The PI for each
affected individual was calculated [PI  EDSS score/time from disease onset
(years)]. Patients were classified as having either BMS or MMS based on EDSS
scores that were maintained over or achieved within designed time intervals
(see Table 5 for clinical details). The BMS cases fall under the relapsing–
remitting clinical subtype wherein minimal disability only (i.e., EDSS 3) was
attained over a period 20 years from disease onset. In contrast, MMS cases,
a subgroup of MS patients acquiring significant disability (i.e., EDSS 6;
requiring the use of a cane or worse) within 5 years of disease onset, had
primary or relapsing–progressive forms of the disease.
Validation of Positive Allelic Associations. To validate positive allelic associa-
tions with disease outcome found in the sporadic cases, a replication cohort
from Sardinia comprised of 62 patients fitting the benign criteria and 19
patients fitting the malignant criteria was used. An additional independent
cohort of affected Canadian sibling pairs (i.e., both siblings affected with the
disease) (n 104) discordant for the allele in question was examined, and the
rates of disease progression between sibling pairs were compared.
HLA-DRB1 Genotyping. Total genomic DNA, extracted from whole blood as
part of the CCPGSMS (42), was used to type HLA-DRB1 alleles via a nonradio-
active high-resolution allele-specific PCR amplification method. All genotypes
were generated by observers blind to pedigree structure and disease status of
the individual. Seventy-two PCRs were carried out to amplify allelotypes
corresponding to alleles HLA-DRB1*01, HLA-DRB1*04, HLA-DRB1*07, HLA-
DRB1*08, HLA-DRB1*09, HLA-DRB1*10, HLA-DRB1*11, HLA-DRB1*12, HLA-
DRB1*13, HLA-DRB1*14, HLA-DRB1*15, HLA-DRB1*16, HLA-DRB1*17,
HLA-DRB1*18, and amplicons for the DRB3, DRB4, and DRB5 genes. Each
HLA-DRB1 genotype was scored twice by independent observers. Hardy–
Weinberg equilibrium was confirmed for allHLA-DRB1 alleles. Allele frequen-
cies were estimated from 202 unrelated and unaffected individuals of Cau-
casian descent. All patients and controls were stratified by HLA-DRB1 allele
frequencies. Additional MS cases (i.e., neither benign nor malignant) derived
from the families of the sporadic MS cohort were included in MS susceptibility
analyses.
SNP Selection and Genotyping. SNP selection and genotyping was conducted
as described (39).
Statistical Analyses. For the sporadic MS cases, the frequencies of HLA-DRB1
alleles in patients and controls were compared bt using a 2 test or Fisher’s
exact test to determine probability values for contingency tables. OR and 95%
C.I. were calculated for each allele. Logistic regression analysis was used to (i)
estimate the relationship between HLA status and affectation status, (ii)
determine the effect of allele interactions on clinical status, and (iii) check for
any relationship between HLA status, affectation, and gender. Where family
data were available, PedCheck (44) was used to check for Mendelian incon-
sistencies, and the TDT was performed by using Genehunter 2.0 (45).
Table 5. Clinical and demographic data on BMS and MMS patients
Feature
Clinical/demographic group
BMS MMS SBMS SMMS CCPGSMS
Sample size, n 112 51 62 19 1,816
Sex ratio, female/male 87:25 (3.48:1) 31:21 (1.48:1) 49:13 (3.76:1) 12:7 (1.7:1) 1310:506 (2.58:1)
Mean age of onset, years 25.1 37.3 26.2 35.3 30.9
Mean duration of disease, years 26 3.6 24.7 4.1
BMS, Canadian BMS EDSS 3 minimum 20 years from disease onset; MMS, Canadian MMS EDSS 6 within 5 years of disease onset; SBMS, Sardinian BMS;
SMMS, Sardinian MMS; CCPGSMS, a sample taken from the CCPGSMS database to show average values.
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For the validation cohort, the effect of HLA-DRB1 on the PI of affected
sibling pairs discordant for a given allele was evaluated by using a Wilcoxon
paired samples test. For SNP analysis we used Haploview (46) and logistic
regression analyses to test for single-marker and haplotypic associations.
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